Role of interferon-γ in murine cytomegalovirus infection

Claire Pomeroy, David Delong, Connie Clabots, Paul Riciputi, Gregory A. Filice

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Interferon-γ has well-documented antiviral and immunomodulatory activity, but its role in the control of cytomegalovirus (CMV) infection is not well studied. In a mouse model of murine CMV (MCMV) disease, interferon-γ concentrations in serum but not in bronchoalveolar lavage fluid increased in response to viral infection. Serum interferon-γ levels peaked at day 2 in the relatively resistant C57BL/6 mice, and, in contrast, did not peak until day 6 in susceptible BALB/c mice. Mice genetically lacking interferon-γ (GKO) were more susceptible to MCMV, although strain differences persisted, with C57BL/6 GKO mice experiencing less severe MCMV disease than BALB/c GKO mice. Treatment of MCMV-infected BALB/c mice with exogenous interferon-γ starting 2 days after viral infection had a modest protective effect at lower interferon-γ, doses (104 units), but interferon-γ therapy markedly increased morbidity and mortality when higher doses (105 units) were used. We conclude that interferon-γ plays a significant role in host response to MCMV and that the cytokine has dose- and time-dependent beneficial and adverse effects.

Original languageEnglish (US)
Pages (from-to)124-133
Number of pages10
JournalJournal of Laboratory and Clinical Medicine
Volume132
Issue number2
StatePublished - Aug 1998
Externally publishedYes

Fingerprint

Muromegalovirus
Cytomegalovirus Infections
Interferons
Virus Diseases
Bronchoalveolar Lavage Fluid
Serum
Inbred C57BL Mouse
Antiviral Agents
Cytokines
Morbidity
Fluids
Mortality

ASJC Scopus subject areas

  • Medicine(all)
  • Pathology and Forensic Medicine

Cite this

Pomeroy, C., Delong, D., Clabots, C., Riciputi, P., & Filice, G. A. (1998). Role of interferon-γ in murine cytomegalovirus infection. Journal of Laboratory and Clinical Medicine, 132(2), 124-133.

Role of interferon-γ in murine cytomegalovirus infection. / Pomeroy, Claire; Delong, David; Clabots, Connie; Riciputi, Paul; Filice, Gregory A.

In: Journal of Laboratory and Clinical Medicine, Vol. 132, No. 2, 08.1998, p. 124-133.

Research output: Contribution to journalArticle

Pomeroy, C, Delong, D, Clabots, C, Riciputi, P & Filice, GA 1998, 'Role of interferon-γ in murine cytomegalovirus infection', Journal of Laboratory and Clinical Medicine, vol. 132, no. 2, pp. 124-133.
Pomeroy C, Delong D, Clabots C, Riciputi P, Filice GA. Role of interferon-γ in murine cytomegalovirus infection. Journal of Laboratory and Clinical Medicine. 1998 Aug;132(2):124-133.
Pomeroy, Claire ; Delong, David ; Clabots, Connie ; Riciputi, Paul ; Filice, Gregory A. / Role of interferon-γ in murine cytomegalovirus infection. In: Journal of Laboratory and Clinical Medicine. 1998 ; Vol. 132, No. 2. pp. 124-133.
@article{5d5395ba8e21467490f36352602d45d9,
title = "Role of interferon-γ in murine cytomegalovirus infection",
abstract = "Interferon-γ has well-documented antiviral and immunomodulatory activity, but its role in the control of cytomegalovirus (CMV) infection is not well studied. In a mouse model of murine CMV (MCMV) disease, interferon-γ concentrations in serum but not in bronchoalveolar lavage fluid increased in response to viral infection. Serum interferon-γ levels peaked at day 2 in the relatively resistant C57BL/6 mice, and, in contrast, did not peak until day 6 in susceptible BALB/c mice. Mice genetically lacking interferon-γ (GKO) were more susceptible to MCMV, although strain differences persisted, with C57BL/6 GKO mice experiencing less severe MCMV disease than BALB/c GKO mice. Treatment of MCMV-infected BALB/c mice with exogenous interferon-γ starting 2 days after viral infection had a modest protective effect at lower interferon-γ, doses (104 units), but interferon-γ therapy markedly increased morbidity and mortality when higher doses (105 units) were used. We conclude that interferon-γ plays a significant role in host response to MCMV and that the cytokine has dose- and time-dependent beneficial and adverse effects.",
author = "Claire Pomeroy and David Delong and Connie Clabots and Paul Riciputi and Filice, {Gregory A.}",
year = "1998",
month = "8",
language = "English (US)",
volume = "132",
pages = "124--133",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Role of interferon-γ in murine cytomegalovirus infection

AU - Pomeroy, Claire

AU - Delong, David

AU - Clabots, Connie

AU - Riciputi, Paul

AU - Filice, Gregory A.

PY - 1998/8

Y1 - 1998/8

N2 - Interferon-γ has well-documented antiviral and immunomodulatory activity, but its role in the control of cytomegalovirus (CMV) infection is not well studied. In a mouse model of murine CMV (MCMV) disease, interferon-γ concentrations in serum but not in bronchoalveolar lavage fluid increased in response to viral infection. Serum interferon-γ levels peaked at day 2 in the relatively resistant C57BL/6 mice, and, in contrast, did not peak until day 6 in susceptible BALB/c mice. Mice genetically lacking interferon-γ (GKO) were more susceptible to MCMV, although strain differences persisted, with C57BL/6 GKO mice experiencing less severe MCMV disease than BALB/c GKO mice. Treatment of MCMV-infected BALB/c mice with exogenous interferon-γ starting 2 days after viral infection had a modest protective effect at lower interferon-γ, doses (104 units), but interferon-γ therapy markedly increased morbidity and mortality when higher doses (105 units) were used. We conclude that interferon-γ plays a significant role in host response to MCMV and that the cytokine has dose- and time-dependent beneficial and adverse effects.

AB - Interferon-γ has well-documented antiviral and immunomodulatory activity, but its role in the control of cytomegalovirus (CMV) infection is not well studied. In a mouse model of murine CMV (MCMV) disease, interferon-γ concentrations in serum but not in bronchoalveolar lavage fluid increased in response to viral infection. Serum interferon-γ levels peaked at day 2 in the relatively resistant C57BL/6 mice, and, in contrast, did not peak until day 6 in susceptible BALB/c mice. Mice genetically lacking interferon-γ (GKO) were more susceptible to MCMV, although strain differences persisted, with C57BL/6 GKO mice experiencing less severe MCMV disease than BALB/c GKO mice. Treatment of MCMV-infected BALB/c mice with exogenous interferon-γ starting 2 days after viral infection had a modest protective effect at lower interferon-γ, doses (104 units), but interferon-γ therapy markedly increased morbidity and mortality when higher doses (105 units) were used. We conclude that interferon-γ plays a significant role in host response to MCMV and that the cytokine has dose- and time-dependent beneficial and adverse effects.

UR - http://www.scopus.com/inward/record.url?scp=0031871978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031871978&partnerID=8YFLogxK

M3 - Article

VL - 132

SP - 124

EP - 133

JO - Translational Research

JF - Translational Research

SN - 1931-5244

IS - 2

ER -